How to Manage Venetoclax Resistance in Chronic Lymphocytic Leukemia
Experts outline treatment options for patients with venetoclax resistance.
Lymphoma
LYMPHOMA ADVISOR
FEATURED CONTENT
-
-
Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity. -
COVID-19 Vaccination and Imaging Misinterpretation: An Interview With Lacey McIntosh, DO, MPH
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making. -
Data From the CAPTIVATE Study’s uMRD Cohort Suggest Role for Fixed-Duration Therapy in CLL/SLL [Q&A]
John N. Allan, MD, a lead author of the CAPTIVATE study, discusses the findings from the uMRD cohort and their implications for the CLL/SLL paradigm. -
Patients Continue to Be Inadequately Informed of Risk for Breast Implant-Associated ALCL
Although the risk for breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) has been well-documented, patients considering breast implants continue to be inadequately informed of the propensity for disease development.
LYMPHOMA NEWS
Brentuximab Vedotin May Improve Outcomes in Anaplastic Large Cell Lymphoma
Loncastuximab Tesirine ‘Could Change Practice’ for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Regimen Deemed Safe, Effective as Bridge to Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma
Older Patients With NHL at High Risk for Treatment-Related Toxicity Events
Ofatumumab Plus Bendamustine Does Not Confer a Survival Benefit in Indolent Non-Hodgkin Lymphoma
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
Loading... 
Loading...